StockMarketWire.com - Hemodynamic monitoring company Lidco said Friday it had won a contract from a public university medical centre in Southern California. The customer had signed a five-year agreement for 15 monitors, converting from their current hemodynamic monitoring provider, the company said.

The centre was recognised as a thought leader in the US in the treatment of Sepsis - the leading cause of death in hospitals and re-admissions.

Lidco's technology had been 'strongly associated with successful treatment protocols for this patient population and there are a number of clinical papers demonstrating the benefits of using LiDCO technology within this patient group,' the company added.

High Usage Programme (HUP) business model continued to build momentum in the US. This 'greatly enhancing revenue visibility and reduces the challenges of closing orders around the year-end,' the company said.

At 8:57am: [LON:LID] LiDCO Group PLC share price was +0.05p at 3.6p



Story provided by StockMarketWire.com